Apatinib plus adebrelimab and chemo for extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that has not been treated yet.
- You must be 18–75 years old and feeling well enough to carry out daily activities (ECOG 0 or 1).
- You need at least one measurable tumor that can be tracked with imaging.
- Your organs must be working well enough, as shown by blood and heart tests.
- If you have had brain metastases, they must be stable and off steroids for at least 1 month before starting the trial.
- You cannot be pregnant or breastfeeding, and must agree to use birth control during and for 6 months after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.